A novel PAX3 mutation in a Korean patient with Waardenburg syndrome type 1 and unilateral branch retinal vein and artery occlusion: a case report
- 205 Downloads
Waardenburg syndrome (WS) is a very rare genetic disorder affecting the neural crest cells. Coexistence of branch retinal vein occlusion (BRVO) and branch retinal artery occlusion (BRAO) in the same eye is also a rare finding. Here we report a case of WS type 1 that was confirmed by a novel mutation with the finding of unilateral BRVO and BRAO.
A 36-year-old, white-haired Korean man presented with a complaint of loss of vision in the inferior visual field of his right eye and hearing loss. He had telecanthus with a medial eyebrow and a hypochromic left iris. Funduscopy showed an ischemic change at the posterior pole in the right eye with sparing of the foveal center as well as retinal hemorrhages and white patches along the superotemporal arcade. Fundus angiography revealed the presence of both BRVO and BRAO, and optical coherence tomography showed thickening and opacification of the retinal layers corresponding to the ischemic area. A blood workup revealed hyperhomocysteinemia and the presence of antiphospholipid antibodies; both are suggestive as the cause of the BRVO and BRAO. Single nucleotide polymorphism analysis confirmed a novel PAX3 mutation at 2q35 (c.91–95 ACTCC deletion causing a frameshift). These findings confirmed a diagnosis of WS type 1.
WS is a heterogeneous inherited disorder of the neural crest cells that causes pigment abnormalities and sensorineural hearing loss. This is the first report of unilateral BRVO and BRAO in a patient with WS. Furthermore, the PAX3 mutation identified in this patient has not been reported previously.
KeywordsWaardenburg syndrome PAX3 gene mutation Hyperhomocysteinemia Branch retinal vein occlusion Branch retinal artery occlusion
Branch retinal artery occlusion
Branch retinal vein occlusion
Endothelin receptor type B
(microphthalmia-associated transcription factor)
(encoding the paired box 3 transcription factor)
(snail homolog 2)
(encoding the Sry bOX10 transcription factor)
Waardenburg syndrome (WS) is a rare heterogeneous inherited disorder of the neural crest cells (NCC) [1, 2] that causes abnormalities in NCC-derived melanocytes, leading to pigment abnormalities and sensorineural hearing loss. Read and Newton identified four types of WS according to the additional symptoms present . In their classification, type 1 (OMIM #193500) and type 2 (OMIM #193510) have similar features, but are distinguished by telecanthus, which is present only in type 1. Musculoskeletal anomalies are found in type 3 (OMIM#148820), while type 4 (OMIM #277580) is associated with Hirschsprung disease. At the molecular level, six genes are involved in this syndrome and have varying degrees of frequency: PAX3 (encoding the paired box 3 transcription factor) is associated with types 1 and 3, MITF (microphthalmia-associated transcription factor) and SNAI2 (snail homolog 2) with type 2, EDN3 (endothelin 3) and EDNRB (endothelin receptor type B) with type 4, and SOX10 (Sry bOX10 transcription factor) with types 2 and 4 .
Coexistence of branch retinal vein occlusion (BRVO) and branch retinal artery occlusion (BRAO) in the same eye is a rare finding. Lee et al. reported 56 cases of coexisting arterial insufficiency in a study of 308 eyes with BRVO . Subsequently, case series of patients with both BRAO and BRVO and comorbid systemic associations were reported [6, 7]. Commonly associated systemic comorbidities included multiple cardiovascular risk factors, cardiac valve disease, hyperhomocysteinemia, a hypercoagulable state, systemic lupus, and vasculitis. Therefore, systemic evaluation is routinely recommended in addition to appropriate treatment in these patients. Coexisting BRVO and BRAO has not been reported in a patient with WS.
Here we describe a patient with WS type 1 who was found to have unilateral BRVO and BRAO and in whom single nucleotide polymorphism analysis identified a novel PAX3 mutation in the 2q35 region.
WS was initially described as an autosomal dominant disorder associated with depigmentation abnormalities and sensorineural hearing loss [1, 2, 4]. Other clinical manifestations, including dysmorphic craniofacial features [2, 8], upper limb abnormalities [2, 9], Hirschsprung disease [3, 10], and neurologic defects , have been reported with variable frequency. WS is now known to consist of a group of genetically heterogenous subtypes, and not all cases are inherited in a dominant manner. Given that the syndrome is caused by a genetic disorder affecting NCCs, the melanocytes of the skin and inner ear, peripheral and enteric nervous systems, and some of the craniofacial and skeletal tissues can in theory be affected [12, 13]. All six genes (PAX3, MITF, EDN3, EDNRB, SOX10, and SNAI2) known to cause WS  are involved in a complex interplay relating to the differentiation and function of melanocytes. Heterozygous mutations in PAX3 are known to be responsible for most cases of WS types 1 and 3.
In this case, we identified a novel PAX3 mutation (c.91–95 ACTCC deletion causing p.Thr31fs) in exon 2, which has not been reported previously. The pathogenicity of this frameshift mutation was validated by in silico prediction using Combined Annotation Dependent Depletion (CADD) version 1.4 . The mutation was predicted to be highly deleterious for PAX3 (CADD score = 34). It is well known that PAX3 mutation is likely to cause WS type 1 [15, 16, 17, 18, 19, 20, 21, 22]. The clinical characteristics in our patient supported a diagnosis of WS type 1, i.e., pigment abnormalities of the hair and left eye, congenital hearing loss, and dystopia canthorum. No musculoskeletal, neurologic, or intestinal anomalies were detected. The main limitation of this report is that the underlying pattern of inheritance of WS in the patient’s family could not be investigated. However, we constructed the family pedigree based on the hearing-impaired phenotype, which suggested that the de novo mutation (c.91-95delACTCC) identified in PAX3 was the likely cause of genetic transmission of hearing loss in the patient’s family. In addition to family genotyping, further studies that include functional analysis are required to explore the genetic mechanism of this novel mutation.
It is of interest that our patient had both BRVO with BRAO in the eye contralateral to the depigmented left eye. Although the relationship is not clear, the angiographic findings suggest that the initiating event was retinal vein occlusion followed by stasis of blood flow. An elevation of intraluminal capillary pressure caused by a patent central retinal artery seemed to result in BRAO in the same quadrant as the BRVO. Considering the favorable visual outcome in this patient after 2 months of follow-up, arterial insufficiency rather than frank obstruction seems more likely. Laboratory investigations identified hyperhomocysteinemia [23, 24] and antiphospholipid antibodies [25, 26] as the possible cause of the unilateral BRVO and BRAO in this young patient. Kadoi et al. have previously reported BRVO of a hypochromic eye in a patient with WS that was considered most likely to be caused by systemic hypertension .
In vitro and animal studies have shown that the homocysteine level in the embryonic stage affects the expression of PAX [28, 29]. The relationship between homocysteine and PAX3 mutation in WS is unclear. However, it is possible that the homocysteine level could be an environmental factor contributing to the variable clinical expression and familial penetrance of phenotypes in WS.
We have encountered a young male patient who presented with a unilateral visual field defect associated with both BRVO and BRAO in his right eye. The diagnosis of WS type 1 was confirmed by his characteristic clinical features and detection of a novel PAX3 mutation at 2q35 (c.91–95 ACTCC deletion). This report is the first to describe coexistence of BRVO and BRAO in association with hyperhomocysteinemia and antiphospholipid antibodies in a patient with WS. Further studies are needed to identify the association between WD and hyperhomocysteinemia.
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2016R1D1A1A02937349).
Availability of data and materials
All data generated or analyzed in this report are included in this published article.
EYC, WC, and CSL analyzed and interpreted the patient data. EYC and CSL were major contributors in writing the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
IRB approval is not required for a case report.
Consent for publication
The risk of identification of the patient was minimized, and we obtained consent to publish from the patient.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 11.Touraine RL, Attie-Bitach T, Manceau E, Korsch E, Sarda P, Pingault V, Encha-Razavi F, Pelet A, Auge J, Nivelon-Chevallier A, et al. Neurological phenotype in Waardenburg syndrome type 4 correlates with novel SOX10 truncating mutations and expression in developing brain. Am J Hum Genet. 2000;66(5):1496–503.CrossRefGoogle Scholar
- 16.Cesca F, Bettella E, Polli R, Cama E, Scimemi P, Santarelli R, Murgia A. A novel mutation of the EYA4 gene associated with post-lingual hearing loss in a proband is co-segregating with a novel PAX3 mutation in two congenitally deaf family members. Int J Pediatr Otorhinolaryngol. 2018;104:88–93.CrossRefGoogle Scholar
- 22.Milunsky JM. Waardenburg Syndrome Type I. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington; 2001.Google Scholar
- 24.Parchand SM. Combined central retinal vein and branch retinal artery occlusion in hyperhomocysteinaemia. BMJ Case Rep. 2016;2016. https://doi.org/10.1136/bcr-2016-218379.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.